Opinion: All the President’s Men

As we all know, President Trump has returned to the White House after a three-day stay at Walter Reed National Military Medical Center, where he was hospitalized with COVID-19. His care is continuing around the clock in the White House Medical Unit by a team of healthcare providers led by Dr. Sean Conley, the personal physician to the President.

There continues to be a cloud of misinformation and a cloak of secrecy regarding his condition, along with questions about why he received such aggressive treatment in the hospital. President Trump is at risk for severe COVID. He’s over 65, he’s obese, and he may have other risk factors of which the public is not aware. It’s concerning to hear that he required supplemental oxygen at least twice over the weekend. His lowest oxygen levels were reported to be 93 or 94 percent. Since oxygen therapy is not routinely given for those levels, evidence-based medicine would suggest that his oxygen levels may have been lower than that.

Although the President got surprisingly aggressive medical treatment in the hospital, he appears not to have received either of the two therapeutics he has been touting publicly: hydroxychloroquine or convalescent plasma. According to news reports, in addition to taking a slew of non-prescription medications, including Vitamin D, zinc, melatonin, aspirin, and the heartburn medication Pepcid, the President was an early recipient of a series of treatments that have only been shown to improve the prognosis in patients who are severely ill with COVID.

He is on dexamethasone, a high-dose steroid. A published drug trial of more than 6,400 patients with COVID who were either receiving continuous oxygen or using a mechanical ventilator showed that a 10-day course of dexamethasone reduced 28-day mortality. But President Trump met neither of those criteria.

The President is also on remdesivir, an antiviral medication. Supplies of this drug are limited, and there’s insufficient data to recommend either for or against its use in patients with mild or moderate COVID-19. He also received a dose of an experimental antibody cocktail made by Regeneron that is designed to boost a patient’s immune system. Keep in mind: this medication has only been delivered to 275 trial patients. As I said, it’s experimental, and it has not received emergency use approval from the Food and Drug Administration (FDA). There’s no data to support the use of either of these treatments, based on the President’s reported condition.

An ethical rule in modern medicine is “first do no harm.” Did President Trump’s doctors ignore that part of the Hippocratic Oath? If these medications were truly indicated, the President was much sicker than his doctors reported. If they were not indicated, then the President is a victim of what some doctors refer to as “VIP syndrome.” VIP syndrome occurs when special treatments are given to famous or well-connected people, regardless of need or documented efficacy.

You and I can’t get the three medications that President Trump got, and that may be a good thing. One reason: the President may be the first person ever to receive all three of those treatments. The possible consequences of this combination are unknown. Another reason: studies show there is no proven benefit, and there’s the possibility of harm, in patients who received dexamethasone, but did not require continuous oxygen. Yet another reason is that high-dose dexamethasone can cause short-term, steroid-induced psychosis and other psychiatric side effects, especially in the elderly.

Just because President Trump has been discharged does not mean that he has recovered from COVID. Physicians taking care of COVID patients use the term “falling off the cliff” to describe a sudden change in acute oxygenation that can occur within the first 7-10 days of this illness. In addition to any potential side effects from the aggressive use of the medications he was given, the President is still at risk for acute worsening in his condition.

Whether he was actually sicker than reported, or he was subjected to overly aggressive “VIP” care, or determined his own time of discharge because he is the President, the next week will be critical in determining President Trump’s medical course and prognosis.

Facebook
Twitter
LinkedIn

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

Trending News

Featured Webcasts

Ask Dr. Hirsch: Clarifying Medicare’s Most Misunderstood Rules – Part 2

Medicare regulations are complex and even seasoned professionals struggle to apply them consistently. Due to overwhelming demand, Dr. Hirsch returns for Part 2 of Ask Dr. Hirsch: Clarifying Medicare’s Most Misunderstood Rules to answer even more of Medicare’s most misunderstood questions, covering inpatient status, observation, SNF access, Medicare Advantage denials, and more. Join Dr. Hirsch as he provides clear, referenced answers to real-world questions submitted by your peers, helping you navigate Medicare compliance with confidence and clarity.

June 18, 2026

Reengineering Utilization Management: Building an Adaptive Model for the New Payer Era

Traditional utilization management models can no longer keep pace with regulatory shifts, payer scrutiny, and operational pressures. In this webcast, Tiffany Ferguson, LMSW, CMAC, ACM, ACPA-C, introduces an Adaptive Model strategy that modernizes UM through role specialization, technology-driven workflows, and proactive, team-based processes. Attendees will learn how to restructure programs to improve efficiency, strengthen clinical collaboration, and enhance financial performance in a rapidly changing healthcare environment.

May 20, 2026

Compliance for the Inpatient Psychiatric Facility (IPF-PPS): Minimizing Federal Audit Findings by Strengthening Best Practices

Federal auditors are intensifying their focus on inpatient psychiatric facilities, using advanced data analytics to spotlight outliers and pursue high‑dollar repayments. In this high‑impact webcast, Michael Calahan, PA, MBA, Compliance Officer and V.P., Hospital & Physician Compliance, breaks down what regulators are really targeting in IPF-PPS admissions, documentation, treatment and discharge planning. Attendees will learn practical steps to tighten processes, avoid common audit triggers and protect reimbursement and reduce the risk of multimillion-dollar repayment demands.

April 9, 2026

Mastering MDM for Accurate Professional Fee Coding

In this timely session, Stacey Shillito, CDIP, CPMA, CCS, CCS-P, CPEDC, COPC, breaks down the complexities of Medical Decision Making (MDM) documentation so providers can confidently capture the true complexity of their care. Attendees will learn practical, efficient strategies to ensure documentation aligns with current E/M guidelines, supports accurate coding, and reduces audit risk, all without adding to charting time.

March 31, 2026

Trending News

Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more

Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!

This Memorial Day, we honor those who gave all for our freedom. Take 20% off sitewide through May 29 with code MEMORIAL26 at checkout

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24